Diagnostic Value of Circulating MicroRNAs for Lung Cancer: a Meta-analysis

Overview

Journal Genet Test Mol Biomarkers

Specialties Genetics
Molecular Biology

Date 2013 Feb 8

PMID 23387316

Citations 8

Authors

Yongchun Shen

Tao Wang

Ting Yang

Qianjing Hu

Chun Wan

Lei Chen

Fuqiang Wen

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is a leading cause of cancer mortality, and it shows a high incidence worldwide. Circulating microRNAs have been proposed as diagnostic indicators of lung cancer, but inconsistent results in the literature have prevented their widespread use in diagnosis. The present meta-analysis aimed to systematically evaluate the diagnostic accuracy of circulating microRNAs for lung cancer.

Methods: Several research databases were searched systematically for studies of the accuracy of circulating microRNAs as diagnostic indicators of lung cancer. Results from different studies were pooled using random-effects models. Summary receiver operating characteristic (SROC) curves were used to assess the overall performance of microRNA-based assays.

Results: Thirteen publications were included in the meta-analysis. The following summary estimates were obtained for the performance of circulating microRNAs in lung cancer diagnosis: sensitivity, 0.85 (95% confidence intervals [CI]: 0.83-0.87); specificity, 0.84 (95% CI: 0.81-0.86); positive likelihood ratio, 5.23 (95% CI: 3.75-7.29); negative likelihood ratio, 0.20 (95% CI: 0.14-0.27); and diagnostic odds ratio, 31.77 (95% CI: 16.98-59.42). The SROC curve indicated a maximum joint sensitivity and specificity of 0.85, with an area under the curve of 0.92.

Conclusion: Circulating microRNAs show significant potential as diagnostic markers of lung cancer. The results of this meta-analysis justify larger, more rigorous studies to confirm such a diagnostic role.

Citing Articles

Serum Exosomes and Their miRNA Load-A Potential Biomarker of Lung Cancer.

Smolarz M, Widlak P Cancers (Basel). 2021; 13(6).

PMID: 33803617 PMC: 8002857. DOI: 10.3390/cancers13061373.

ZNF582 methylation as a potential biomarker to predict cervical intraepithelial neoplasia type III/worse: A meta-analysis of related studies in Chinese population.

Li N, He Y, Mi P, Hu Y Medicine (Baltimore). 2019; 98(6):e14297.

PMID: 30732145 PMC: 6380660. DOI: 10.1097/MD.0000000000014297.

PAX1 and SOX1 methylation as an initial screening method for cervical cancer: a meta-analysis of individual studies in Asians.

Chen Y, Cui Z, Xiao Z, Hu M, Jiang C, Lin Y Ann Transl Med. 2016; 4(19):365.

PMID: 27826568 PMC: 5075846. DOI: 10.21037/atm.2016.09.30.

Long noncoding RNAs as auxiliary biomarkers for gastric cancer screening: A pooled analysis of individual studies.

Cui Z, Chen Y, Xiao Z, Hu M, Lin Y, Chen Y Oncotarget. 2016; 7(18):25791-800.

PMID: 27015554 PMC: 5041944. DOI: 10.18632/oncotarget.8268.

Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study.

Cui Z, Lin D, Song W, Chen M, Li D Tumour Biol. 2014; 36(2):829-39.

PMID: 25296735 DOI: 10.1007/s13277-014-2700-8.

References

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

Leeflang M, Deeks J, Gatsonis C, Bossuyt P . Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008; 149(12):889-97. PMC: 2956514. DOI: 10.7326/0003-4819-149-12-200812160-00008. View

Whiting P, Weswood M, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J . Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006; 6:9. PMC: 1421422. DOI: 10.1186/1471-2288-6-9. View

Aberle D, Berg C, Black W, Church T, Fagerstrom R, Galen B . The National Lung Screening Trial: overview and study design. Radiology. 2010; 258(1):243-53. PMC: 3009383. DOI: 10.1148/radiol.10091808. View

Bishop J, Benjamin H, Cholakh H, Chajut A, Clark D, Westra W . Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010; 16(2):610-9. DOI: 10.1158/1078-0432.CCR-09-2638. View

Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F . MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011; 108(9):3713-8. PMC: 3048155. DOI: 10.1073/pnas.1100048108. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

Walter S . Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002; 21(9):1237-56. DOI: 10.1002/sim.1099. View

Deeks J, Altman D . Diagnostic tests 4: likelihood ratios. BMJ. 2004; 329(7458):168-9. PMC: 478236. DOI: 10.1136/bmj.329.7458.168. View

10.

Bianchi F, Nicassio F, Marzi M, Belloni E, DallOlio V, Bernard L . A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011; 3(8):495-503. PMC: 3377091. DOI: 10.1002/emmm.201100154. View

11.

Lu X, Yang X, Zhang Z, Wang D . [meta-analysis of serum tumor markers in lung cancer]. Zhongguo Fei Ai Za Zhi. 2010; 13(12):1136-40. PMC: 6426739. DOI: 10.3779/j.issn.1009-3419.2010.12.11. View

12.

Jeong H, Kim E, Lee J, Lee J, Yoo H, Kim J . Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Rep. 2011; 4(2):383-7. DOI: 10.3892/mmr.2011.430. View

13.

Leidinger P, Keller A, Borries A, Huwer H, Rohling M, Huebers J . Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer. 2011; 74(1):41-7. DOI: 10.1016/j.lungcan.2011.02.003. View

14.

Cho W . Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer. Expert Rev Mol Diagn. 2011; 11(8):763-6. DOI: 10.1586/erm.11.71. View

15.

Stiles B, Altorki N . Screening for lung cancer: challenges for the thoracic surgeon. Surg Oncol Clin N Am. 2011; 20(4):619-35. DOI: 10.1016/j.soc.2011.07.001. View

16.

Shen J, Liu Z, Todd N, Zhang H, Liao J, Yu L . Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011; 11:374. PMC: 3175224. DOI: 10.1186/1471-2407-11-374. View

17.

Shen J, Todd N, Zhang H, Yu L, Lingxiao X, Mei Y . Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2010; 91(4):579-87. PMC: 3130190. DOI: 10.1038/labinvest.2010.194. View

18.

Welch H, Black W . Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102(9):605-13. DOI: 10.1093/jnci/djq099. View

19.

Lin P, Yang P . Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med. 2011; 3(8):436-7. PMC: 3377090. DOI: 10.1002/emmm.201100155. View

20.

Qi J, Mu D . MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med. 2012; 6(2):134-55. PMC: 3725603. DOI: 10.1007/s11684-012-0188-4. View